Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Melanoma 19Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Pancreatic Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Gastrointestinal Stromal Tumors 2Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Thyroid Neoplasms 1Solid Tumor 1Soft Tissue Neoplasms 1Skin Neoplasms 1Peripheral Nervous System Neoplasms 1Non-small Cell Carcinoma 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1Gliosarcoma 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Recurrence × binimetinib × Clear all
NCT02834364 2023-11-24

GMMG-BIRMA

University of Heidelberg Medical Center

Phase 2 Completed
12 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown
96 enrolled
Thoracic

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡